Surrozen Inc (SRZN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $16.61 (-1.95%), Market cap $0.31B, 52-week low–high $7.65 ~ $34.13.
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or I
Financial statements, price targets, institutional (13F) holdings and related news for Surrozen Inc are updated in real time on BlackAll Trade.
Surrozen Inc trades at $16.61 (-1.95%). Real-time quotes and charts are available on BlackAll Trade.
Surrozen Inc has a market cap of about $0.31B.
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutic